Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

OBJECTIVE: To assess the long-term (3 year) efficacy and safety of secukinumab in patients with active psoriatic arthritis (PsA) in the extension phase of the FUTURE 1 study (NCT01892436). METHODS: Following the 2-year core trial, eligible patients receiving subcutaneous secukinumab 150 or 75 mg ent...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J, Kavanaugh, Arthur, Reimold, Andreas, Tahir, Hasan, Rech, Jürgen, Hall, Stephen, Geusens, Piet, Pellet, Pascale, Delicha, Evie Maria, Mpofu, Shephard, Pricop, Luminita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109799/
https://www.ncbi.nlm.nih.gov/pubmed/30167329
http://dx.doi.org/10.1136/rmdopen-2018-000723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109799/
https://www.ncbi.nlm.nih.gov/pubmed/30167329
http://dx.doi.org/10.1136/rmdopen-2018-000723

Ejemplares similares